Hepatitis C and drug use: Epidemiological characteristics, screening, natural history, and treatment;Hépatite C et usage de drogue: Épidémiologie, dépistage, histoire naturelle et traitement

Gastroenterologie Clinique et Biologique

Volumn 26, Issue SPEC. 2, 2002, Pages

  Lucidarme, Damien ^a  

^a Centre Hospitalier Saint Philibert GHICL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

CONFERENCE PAPER; DISEASE COURSE; DRUG ABUSE; HEPATITIS C; INCIDENCE; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; PREVALENCE; REINFECTION; RISK FACTOR; SCREENING TEST;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; FRANCE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HEROIN DEPENDENCE; HUMANS; INTERFERONS; PREVALENCE; PRISONS; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; RIBAVIRIN; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 0036262377     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (91)

1. Risk factors for the transition from noninjection to injection drug use and accompanying AIDS risk behavior in a cohort of drug users
2. Infections à VIH, VHC et VHB chez les résidents des centres de soins spécialisés pour toxicomanes avec hébergement 1993-1998
3. Unsafe injecting practices among attendees of syringe exchange programmes in France
4. Accuracy of perceptions of hepatitis B and C status: Cross sectional investigation of opiate addicts in treatment
5. Assessment of a hepatitis C virus antibody assay in saliva for epidemiological studies
6. Prevalence and incidence rate of HIV. Hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995
7. Large decline in injecting drug use in Amsterdam, 1986-1998: Explanatory mechanisms and determinants of injecting transitions
8. Prevalence of Hepatitis C among injection drug users in England and Wales: Is harm reduction working?
9. Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam
10. Infection par le virus de l'hépatite C en milieu carcéral
11. Routes of infection, viremia and liver disease in blood donors found to have hepatitis C virus infection
12. Prevalence of antibodies to hepatitis C virus and association with intravenous drug abuse and tattooing in a national prison in Norway
13. A longitudinal study on the incidence and transmission patterns of HIV, HBV, HCV infection among drug users in Amsterdam
14. Incidence and risk factors for hepatitis C among drug users in Baltimore, Maryland
15. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995
16. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users
17. Cumulative incidence of hepatitis C seroconversion in a cohort of seronegative injecting drug users
18. Sharing of drug preparation equipment as a risk factor for hepatitis C
19. Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence
20. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: Retrospective cohort study
21. Etude prospective multicentrique de l'incidence et des facteurs de risque de l'infection par le virus de l'hépatite C dans un groupe de toxicomanes du Nord-Est de la France
22. Hepatitis C in intravenous drug users
23. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland
24. Prévalence des marqueurs des hépatites C, B, et D, et aspects histopathologiques dans un groupe de toxicomanes intraveineux
25. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco
26. Risques viraux et usage de drogue. Peut-on revenir sur un rendez-vous manqué?
27. The force of numbers: Why hepatitis C is spreading among Australian injecting drug users while HIV is not
28. Prise en charge de l'infection par le virus de l'hépatite C dans la région Poitou-Charentes
29. Stratégies de dépistage de l'hépatite virale C en médecine générale
30. Evaluation de trois stratégies de dépistage de l'hépatite C en consultation hospitalière de Médecine générale et dans un Centre de dépistage anonyme et gratuit du virus de l'immunodéficience humaine
31. Prevalence and incidence of hepatitis C infection among male prison inmates in Maryland
32. Spread of bloodborne viruses among Australian prison entrants
33. Prevalence and incidence of bloodborne viral infections among Danish prisoners
34. Transmission of hepatitis C within Australian prisons
35. Knowledge of HIV serostatus and preventive behaviour among European injecting drug users
36. HCV status knowledge and risk behaviours amongst intravenous drug users
37. Clinical evaluation of oral fluid samples for diagnosis of viral hepatitis
38. The use of oral fluid for hepatitis C antibody screening
39. Modified enzyme immunoassay to detect hepatitis C virus antibodies in oral fluid
40. Detection of antibodies against hepatitis C virus in saliva: A marker of viral replication
41. Evaluation of hepatitis C antibody testing in saliva specimens collected by two different systems in comparison with HCV antibody and HCV RNA in serum
42. Le diagnostic de l'infection par le virus de l'hépatite C [VHC] sur prélèvement salivaire pourrait permettre de dépister tous les sujets virémiques
43. Treatment of acute hepatitis C with interferon alfa-2b
44. Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome
45. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
46. Conférence internationale de consensus sur l'hépatite C. Conclusions
47. Natural history of liver fibrosis progressïon in patients with chronic hepatitis C
48. Impact of alcohol on the histological and clinical progression of hepatitis C infection
49. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users
50. Liver fibrosis progression in human immunodeficiency virus and hepatic virus coinfected patients
51. Characteristics of patients with dual infection by hepatitis B and C viruses
52. Hepatitis C virus infection
53. An algorithm for the grading of activity in chronic hepatitis C
54. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French survey of 6,664 patients
55. Clinical sequelae of hepatitis C acquired from injection drug use
56. Estimating progression to cirrhosis in chronic hepatitis C virus infection
57. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C
58. Assessment of long term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975
59. The natural history of hepatitis C virus infection. Host, viral and environmental factors
60. Rapidité d'évolution vers la cirrhose après hépatite C: Influence de l'âge au moment de la contamination par le virus
61. Noninvasive diagnosis of hepatic fibrosis or cirrhosis
62. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study
63. Long-term mortality after transfusion-associated non-A, non-B hepatitis
64. Mortality trends in a cohort of opiate addicts, Catalonia, Spain
65. Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and HIV-negative drug users
66. A 33-year follow-up of narcotics addicts
67. Epidémiologie de l'infection virale C chez 1 304 sujets VHC positif. Variations en fonction du mode de contamination et de l'année du diagnostic
68. Epidémiologie de l'hépatite C dans un centre hospitalier général. Prise en charge et histoire naturelle en fonction du mode de découverte
69. Conclusions et recommandations du jury. Texte long. Hépatite C: Dépistage et traitement
70. Panel Statement: Management of hepatitis C
71. Treatment of chronic hepatitis C in active drug users
72. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: Results of a randomised trial
73. Effets de l'interféron alpha 2a pégylé (Pegasys) associé à la ribavirine dans l'hépatite chronique virale C. Etude randomisée multicentrique
74. Suivi à 2 ans d'une cohorte de patients sous buprénorphine haut dosage. Résultats de l'étude SPE-SUB [suivi pharmaco-épidémiologique du Subutex® en médecine de ville]
75. Hepatitis C virus genotypes in France: Relationship with epidemiology, pathogenicity and response to interferon therapy
76. Treatment of hepatitis C infection in injection drug users
77. Managing chronic hepatitis C acquired through intravenous drug use
78. Randomised trial of interferon alfa 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
79. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
80. Que dire, que faire en cas de toxicomanic accompagnée d'hé-patite virale C?
81. Effets secondaires de l'interféron alpha
82. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon
83. Lack of protective immunity against reinfection with hepatitis C virus
84. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children
85. Two successive hepatitis C virus infections in an intravenous drug user
86. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
87. Access to antiretroviral treatment among French HIV infected drug users: The influence of continued drug use